Screening programmes for tuberculosis (TB) among immigrants rarely consider the heterogeneity of
risk related to migrants’ country of origin. We assess the performance of a large screening programme in asylum seekers by analysing (i) the difference in yield and numbers needed to screen (NNS) by c...ountry and WHO-reported TB burden, (ii) the possible impact of screening thresholds on sensitivity, and (iii) the value of WHO-estimated TB burden to improve the prediction accuracy of screening yield.
more
Hindawi Publishing Corporation
Tuberculosis Research and Treatment
Volume 2015, Article ID 752709, 7 pages
Rev Panam Salud Publica 45, 2021 |
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Rapport final de Knowledge for Health (Connaissances pour la Santé).
Le présent rapport donne les principaux résultats issus de l’analyse de la situation menée par le Centre de Formation et de Recherche en Santé en Santé de la Reproduction (CEFOREP), en collaboration avec FHI, dans les ré...gions de Dakar (Niveau Central, District Nord, District de Pikine et District de Mbao), Kaolack (District de Kasnack) et Saint-Louis (District de Saint-Louis). Il passe en revue les questions concernant la gestion de l’information en santé, les besoins en information, les outils et technologies utilisés, le niveau d’accès aux infrastructures de communication en santé ainsi que le fonctionnement des réseaux professionnels existants. Le rapport relate aussi les questions concernant l’utilisation de la planification familiale, avant de déboucher sur des recommandations.
more
Lancet Infect Dis 2022;
22: 222–4
HIV infection, due to the immunosuppressant that leads, nowadays constitutes an aggravating factor of endemic tuberculosis. Tuberculosis remains a huge burden to human health, even in the early 21st century. The situation is deteriorating in many countries, particularly because of the synergy with t...he HIV epidemic and the emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR) tuberculosis. The urgent development of new tools that can improve the diagnosis, prevention and/or treatment of tuberculosis and other major mycobacterium diseases depends largely on the progress of basic and applied research. Faced with this situation, there is an urgent need for effective strategies and actions to permanently solve the problem of this endemic disease whose impact is too negative on people’s lives.
more
International Journal of Infectious Diseases 32 (2015) 111–117
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
13 May 2021
To avoid a reversal of progress from the adverse impacts of the COVID-19 pandemic, new knowledge and lessons from successful programmatic innovations are urgently needed to improve TB prevention and care. Experience can provide evidence for innovative approaches and strategies to mainta...in and scale up high-quality TB services. WHO therefore called for case studies on programmatic innovations that address emerging challenges in TB prevention and care during the pandemic in order to collect and disseminate the findings to the TB community. Between November 2020 and February 2021, a total of 23 case studies relevant to the call were accepted from 19 countries in the six regions of WHO. The lessons learnt from these country activities to ensure the continuity of essential services like TB care in the face of the crippling crisis may also inform strategies for minimizing the impact of future emerging pathogens on health services.
more
Guidelines for social mobilization
TB and poverty; TB and children; TB and women; TB, migrants and refugees; TB and prisons
WHO/CDS/STB/2001.9
Original: English; Distribution: Limited
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
РУКОВОДСТВО ПО БИОЛОГИЧЕСКОЙ БЕЗОПАСНОСТИ ЛАБОРАТОРНЫХ ИССЛЕДОВАНИЙ ПРИ ТУБЕРКУЛЕЗЕ.